ID   CAOV3 (R)
AC   CVCL_C8XN
DR   Wikidata; Q123030855
RX   PubMed=33519462;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136Ter (c.406C>T); ClinVar=VCV001802458; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0201 ! Caov-3
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 05-10-23; Last updated: 30-01-24; Version: 2
//
RX   PubMed=33519462; DOI=10.3389/fphar.2020.600994;
RA   Zhang Y.-Q., Gan H.-Y., Zhao F., Ma X.-M., Xie X.-F., Huang R., Zhao J.;
RT   "CPEB4-promoted paclitaxel resistance in ovarian cancer in vitro
RT   relies on translational regulation of CSAG2.";
RL   Front. Pharmacol. 11:600994.1-600994.10(2020).
//